Option chain shows key data for Polyrizon's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Polyrizon.

Polyrizon (NASDAQ:PLRZ) Stock, Option Chain

Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Equities

News

Small Cap

Movers

PLRZ

Polyrizon shares rise after disclosing the publication of a national phase patent application for nasal protection and drug delivery technologies.

Why Is Development-Stage Biotech Company Polyrizon Stock Surging Today?

Crude Oil 6- logo

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CRVS

KULR

RNAZ

Crude Oil Gains Over 1%, General Mills Shares Fall

pharmaceutical drug medicine FDA

Polyrizon shares are moving higher after the company announced it secured a manufacturing agreement with Eurofins CDMO Amatsiaquitaine.

What&#39;s Going On With Polyrizon Shares Wednesday?

Polyrizon Ltd

Press Releases

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

Health Care

General

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Polyrizon Ltd. Announces $17.0 Million Private Placement

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

CMND

CSE:CMND

Abpro Hldgs

BioAtla

BioVie

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Curis

CEL-SCI

Elevation Oncology

Equillium

GlycoMimetics

IN8bio

Kairos Pharma

Leap Therapeutics

Lisata Therapeutics

MetaVia

Mural Oncology

Nanoviricides

Ovid Therapeutics

BiomX

Polyrizon

Portage Biotech

Spruce Biosciences

Synlogic

Unity Biotechnology

Comments

Polyrizon

Polyrizon (PLRZ) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga